Protein toxins: Intracellular trafficking for targeted therapy

Gene Therapy

Volumn 12, Issue 18, 2005, Pages 1360-1368

  Johannes, L ^a   Decaudin, D ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

Immunotherapy; Immunotoxin; Retrograde transport; Shiga toxin B subunit; Tumor targeting

Indexed keywords

ANTIBODY; BACTERIAL TOXIN; CORTICOSTEROID; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; FLUDARABINE; IMMUNOTOXIN; IMMUNOTOXIN LMB2; LIGAND; NEUTRALIZING ANTIBODY; PLANT TOXIN; PSEUDOMONAS EXOTOXIN; SHIGA TOXIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ARTHRALGIA; BACKACHE; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; BURKITT LYMPHOMA; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOMA; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLOGY; DIARRHEA; DRUG FEVER; DRUG SYNTHESIS; DRUG TARGETING; DYSPNEA; EDEMA; FLU LIKE SYNDROME; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INJECTION SITE REACTION; INTRACELLULAR SPACE; LIVER TOXICITY; MELANOMA; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; PAIN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; T CELL LYMPHOMA; THORAX PAIN; VASCULAR DISEASE; VOMITING;

CYTOPLASM; DENDRITIC CELLS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS; PROTEIN SUBUNITS; PROTEIN TRANSPORT; SHIGA-LIKE TOXIN II; T-LYMPHOCYTES, CYTOTOXIC;

BACTERIA (MICROORGANISMS); PSEUDOMONAS; PSEUDOMONAS EXOTOXIN;

EID: 30744471419     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302557     Document Type: Review

References (114)

1. Dyba M, Tarasova NI, Michejda CJ. Small molecule toxins targeting tumor receptors. Curr Pharm Des 2004; 10: 2311-2334.
2. Vallera DA et al. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 2002; 94: 597-606.
3. Morokoff AP, Novak U. Targeted therapy for malignant gliomas. J Clin Neurosci 2004; 11: 807-818.
4. Frankel AE et al. Immunotoxin therapy of hematologic malignancies. Semin Oncol 2003; 30: 545-557.
5. Chovnick A et al. A recombinant, membrane-acting immunotoxin. Cancer Res 1991; 51: 465-467.
6. Choo AB, Dunn RD, Broady KW, Raison RL. Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Exp Purif 2002; 24: 338-347.
7. Gasanov SE, Rael ED, Gasanov NE, Vernon LP. In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin. Cancer Immunol Immunother 1995; 41: 122-128.
8. Hinman CL, Tang HP. A membrane-lytic immunoconjugate selective for human tumor T-lymphocytes. Int J Immunopharmacol 1998; 20: 467-478.
9. LeMaistre CF et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399-405.
10. Olsen E et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388.
11. Frankel AE et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 3555-3561.
12. Dang NH et al. Phase II study of denileukin diftitox for relapsed/ refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095-4102.
13. Frankel AE et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8: 1004-1013.
14. Weber F et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003; 64: 125-137.
15. Rand RW et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000; 6: 2157-2165.
16. Sampson JH et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65: 27-35.
17. Posey JA et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8: 3092-3099.
18. Kreitman RJ et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-1636.
19. Azemar M et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003; 82: 155-164.
20. Baluna R et al. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: Insights into toxin-mediated vascular damage. Exp Cell Res 2000; 258: 417-424.
21. Siegall CB et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 1997; 3: 339-345.
22. Amlot PL et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-2633.
23. Kreitman RJ et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241-247.
24. Sausville EA et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 1995; 85: 3457-3465.
25. Fenstermacher J, Kaye T. Drug 'diffusion' within the brain. Ann NY Acad Sci 1988; 531: 29-39.
26. Hall PD et al. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001; 100: 191-197.
27. Brodsky FM et al. Biological basket weaving: Formation and function of dathrin-coated vesicles. Annu Rev Cell Dev Biol 2001; 17: 517-568.
28. Moya M et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J Cell Biol 1985; 101: 548-559.
29. Abrami L et al. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated dathrin-dependent process. J Cell Biol 2003; 160: 321-328.
30. Naglich JG, Metherall JE, Russell DW, Eidels L. Expression cloning of a diphtheria toxin receptor: Identity with a heparin-binding EGF-like growth factor precursor. Cell 1992; 69: 1051-1061.
31. Bradley KA et al. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414: 225-229.
32. Montesano R, Roth J, Robert A, Ord L. Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 1982; 296: 651-653.
33. Tran D et al. Ligands internalized through coated or noncoated invaginations follow a common intracellular pathway. Proc Natl Acad Sci USA 1987; 84: 7957-7961.
34. Sandvig K, Olsnes S, Petersen OW, van Deurs B. Acidification of the cytosol inhibits endocytosis from coated pits. J Cell Biol 1987; 105: 679-689.
35. Saint-Pol A et al. Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev Cell 2004; 6: 525-538.
36. Lauvrak SU, Torgersen ML, Sandvig K. Efficient endosome-to-Golgi transport of Shiga toxin is dependent on dynamin and clathrin. J Cell Sci 2004; 117: 2321-2331.
37. Nichols BJ et al. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 2001; 153: 529-541.
38. Kirkham M et al. Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J Cell Biol 2005; 168: 465-476.
39. Sandvig K et al. Endocytosis from coated pits of Shiga toxin: A glycolipid-binding protein from Shigella dysenteriae 1. J Cell Biol 1989; 108: 1331-1343.
40. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998; 141: 929-942.
41. Katagiri YU et al. Activation of src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem 1994; 274: 35278-35282.
42. Falguières T et al. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent resistant membranes. Mol Biol Cell 2001; 12: 2453-2468.
43. Johannes L, Lamaze C. Clatrin-dependent or not: Is it still the question? Traffic 2002; 3: 443-451.
44. Shogomori H, Futerman AH. Cholera toxin is found in detergent-insoluble rafts/domains at the cell surface of hippocampal neurons but is internalized via a raft-independent mechanism. J Biol Chem 2001; 276: 9182-9188.
45. Parton RG. Caveolae - from ultrastructure to molecular mechanisms. Nat Rev Mol Cell Biol 2003; 4: 162-167.
46. van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 2003; 13: 92-100.
47. Oh P, McIntosh DP, Schnitzer JE. Dynamin at the neck of Caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J Cell Biol 1998; 141: 101-114.
48. Henley JR, Krueger EW, Oswald BJ, McNiven MA. Dynamin-mediated internalization of caveolae. J Cell Biol 1998; 141: 85-99.
49. Singh RD et al. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol Biol Cell 2003; 14: 3254-3265.
50. Thomsen P, Roepstorff K, Stahlhut M, van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 2002; 13: 238-250.
51. Orlandi PA, Fishman PH. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol 1998; 141: 905-915.
52. Torgersen ML, Skretting G, van Deurs B, Sandvig K. Internalization of cholera toxin by different endocytic mechanisms. J Cell Sci 2001; 114: 3737-3747.
53. Nichols BJ. A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complex. Nat Cell Biol 2002; 15: 15.
54. Le PU, Guay G, Altschuler Y, Nabi IR. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J Biol Chem 2002; 277: 3371-3379.
55. Sharma DK et al. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell 2004; 15: 3114-3122.
56. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001; 3: 473-483.
57. Sabharanjak S, Sharma P, Parton RG, Mayor S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell 2002; 2: 411-423.
58. Lord JM, Roberts LM. Retrograde transport: Going against the flow. Curr Biol 1998; 8: R56-R58.
59. Sandvig K, van Deurs B. Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J 2000; 19: 5943-5950.
60. Johannes L, Goud B. Surfing on a retrograde wave: How does Shiga toxin reach the endoplasmic reticulum? Trends Cell Biol 1998; 8: 158-162.
61. Simpson JC et al. Ricin A chain utilises the endoplasmic reticulum-associated protein degradation pathway to enter the cytosol of yeast. FEBS Lett 1999; 459: 80-84.
62. Wesche J, Rapak A, Olsnes S. Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol. J Biol Chem 1999; 274: 34443-34449.
63. Lord JM et al. Retrograde transport of toxins across the endoplasmic reticulum membrane. Biochem Soc Trans 2003; 31: 1260-1262.
64. Mallard F, Johannes L. Shiga toxin B-subunit as a tool to study retrograde transport. In: Philpott D, Ebel F (eds). Methods in Molecular Medicine. Shiga Toxin Methods and Protocols, Vol 73, Chapter 17. Humana Press: Totowa, New Jersey, 2002, pp 209-220.
65. Mallard F et al. Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6 isoform. J Cell Biol 2002; 156: 653-664.
66. Tai G et al. Participation of syntaxin 5/Ykt6/GS28/GS15 SNARE complex in transport from the early/recycling endosome to the TGN. Mol Biol Cell 2004; 15: 4011-4022.
67. Natarajan R, Linstedt AD. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. Mol Biol Cell 2004; 15: 4798-4806.
68. Lu L, Tai G, Hong W. Autoantigen Golgin-97, an effector of Arl1 GTPase, participates in traffic from the endosome to the trans-Golgi network. Mol Biol Cell 2004; 15: 4426-4443.
69. Wolf AA, Fujinaga Y, Lencer WI. Uncoupling of the cholera toxin-G(M1) ganglioside receptor complex from endocytosis, retrograde Golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol. J Biol Chem 2002; 277: 16249-16256.
70. Ramegowda B, Tesh VL. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun 1996; 64: 1173-1180.
71. Tesh VL, Ramegowda B, Samuel JE. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 1994; 62: 5085-5094.
72. Hoey DE et al. Verotoxin 1 binding to intestinal crypt epithelial cells results in localization to lysosomes and abrogation of toxicity. Cell Microbiol 2003; 5: 85-97.
73. Llorente A et al. Expression of mutant dynamin inhibits toxicity and transport of endocytosed ricin to the Golgi apparatus. J Cell Biol 1998; 140: 553-563.
74. Grimmer S, Iversen TG, van Deurs B, Sandvig K. Endosome to Golgi transport of ricin is regulated by cholesterol. Mol Biol Cell 2000; 11: 4205-4216.
75. Lauvrak SU, Llorente A, Iversen TG, Sandvig K. Selective regulation of the Rab9-independent transport of ricin to the Golgi apparatus by calcium. J Cell Sci 2002; 115: 3449-3456.
76. Birkeli KA et al. Endosome-to-Golgi transport is regulated by protein kinase A type II alpha. J Biol Chem 2003; 278: 1991-1997.
77. Pelkmans L, Burli T, Zerial M, Helenius A. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 2004; 118: 767-780.
78. Pelham HR. The dynamic organisation of the secretory pathway. Cell Struct Funct 1996; 21: 413-419.
79. Cosson P, Letourneur F. Coatomer (COPI)-coated vesicles: Role in intracellular transport and protein sorting. Curr Opin Cell Biol 1997; 9: 484-487.
80. Johannes L, Tenza D, Antony C, Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J Biol Chem 1997; 272: 19554-19561.
81. Fujinaga Y et al. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to the endoplasmic reticulum. Mol Biol Cell 2003; 14: 4783-4793.
82. Jackson ME et al. The KDEL retrieval system is exploited by pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. J Cell Sci 1999; 112: 467-475.
83. Chen A, Hu T, Mikoryak C, Draper RK. Retrograde transport of protein toxins under conditions of COPI dysfunction. Biochim Biophys Acta 2002; 1589: 124-139.
84. Chen A, AbuJarour RJ, Draper RK. Evidence that the transport of ricin to the cytoplasm is independent of both Rab6A and COPI. J Cell Sci 2003; 116: 3503-3510.
85. Guermonprez P, Amigorena S. Pathways for antigen cross presentation. Springer Semin Immunopathol 2005; 26: 257-271.
86. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5: 678-684.
87. Smith DC et al. 1st class ticket to class I: Protein toxin as pathfinders for antigen presentation. Traffic 2002; 3: 697-704.
88. Haicheur N et al. The B-subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165: 3301-3308 (*principal investigators).
89. Lee R-S et al. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol 1998; 28: 2726-2737.
90. Haicheur N et al. The B-subunit of Shiga toxin coupled to full-size protein elicits humoral and cellular immune responses associated with a TH1 dominant polarization. Int Immunol 2003; 15: 1161-1171 (*principal investigators).
91. Fayolle C et al. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol 1996; 156: 4697-4706.
92. Saron MF et al. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 1997; 94: 3314-3319.
93. Fayolle C et al. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 1999; 162: 4157-4162.
94. Schlecht G et al. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 2004; 173: 6089-6097.
95. Fayolle C, Bauche C, Ladant D, Leclerc C. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8(+) T-cell epitopes to dendritic cells and elicits CTL in vivo. Vaccine 2004; 23: 604-614.
96. Guermonprez P et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 2001; 193: 1035-1044.
97. Wiels J, Fellous M, Tursz T. Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci USA 1981; 78: 6485-6488.
98. Cooling LL, Zhang de S, Naides SJ, Koerner TA. Glycosphingolipid expression in acute nonlymphocytic leukemia: Common expression of Shiga toxin and parvovirus B19 receptors on early myeloblasts. Blood 2003; 101: 711-721.
99. Arab S et al. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res 1997; 9: 553-563.
100. LaCasse EC et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999; 94: 2901-2910.
101. Kang JL, Rajpert-De Meyts E, Wiels J, Skakkebaek NE. Expression of the glycolipid globotriaosylceramide (Gb3) in testicular carcinoma in situ. Virchows Arch 1995; 426: 369-374.
102. Farkas-Himsley H et al. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci USA 1995; 92: 6996-7000.
103. Salhia B et al. The treatment of malignant meningioma with verotoxin. Neoplasia 2002; 4: 304-311.
104. Ishitoya S et al. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol 2004; 171: 1309-1313.
105. Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003; 6: 129-141.
106. LaCasse EC et al. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 1996; 88: 1561-1567.
107. Bast DJ et al. Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30. Infect Immun 1997; 65: 2978-2982.
108. Chart H, Law D, Rowe B, Acheson DW. Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: Absence of antibodies to Vero cytotoxin 1 (VT1) or VT2. J Clin Pathol 1993; 46: 1053-1054.
109. Ludwig K et al. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2001; 39: 2272-2279.
110. Levine MM et al. Antibodies to Shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol 1992; 30: 1636-1641.
111. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996; 4: 147-153.
112. Miura Y et al. Peptides binding to a Gb3 mimic selected from a phage library. Biochim Biophys Acta 2004; 1673: 131-138.
113. Johannes L, Goud B. Facing inward from compartment shores: How many pathways were we looking for? Traffic 2000; 1: 119-123.
114. Falguières T, Johannes L. Shiga toxin B-subunit binds to the chaperon BiP and the nucleolar protein B23. Biol Cell (in press).